Sol-Gel Technologies: Topical Skin Cancer Inhibitor in Focus of Wall Street

Cantor Fitzgerald rates the stock as "Overweight" with a target of $200. The analyst points to an attractive risk-reward profile ahead of new study data. For the active ingredient SGT-610 for the treatment of Gorlin syndrome, the company expects decisive results by the end of November 2026. Sol-Gel Technologies plans to launch in the US independently and is fully financed with €49.3 million until early 2028. Dermatology Focus Meets Unmet Medical Need Sol-Gel Technologies (SLGL) focuses on developing topical dermatology preparations for rare...